These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36003057)

  • 1. Liver X receptor: a potential target in the treatment of atherosclerosis.
    Savla SR; Prabhavalkar KS; Bhatt LK
    Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver X receptors as potential therapeutic targets in atherosclerosis.
    Zhu Y; Li Y
    Clin Invest Med; 2009 Oct; 32(5):E383-94. PubMed ID: 19796580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
    Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
    J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
    Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
    Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
    Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
    Breevoort SR; Angdisen J; Schulman IG
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol efflux is LXRα isoform-dependent in human macrophages.
    Ma AZ; Song ZY; Zhang Q
    BMC Cardiovasc Disord; 2014 Jul; 14():80. PubMed ID: 24996838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE.
    Bradley MN; Hong C; Chen M; Joseph SB; Wilpitz DC; Wang X; Lusis AJ; Collins A; Hseuh WA; Collins JL; Tangirala RK; Tontonoz P
    J Clin Invest; 2007 Aug; 117(8):2337-46. PubMed ID: 17657314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages.
    Shrestha E; Hussein MA; Savas JN; Ouimet M; Barrett TJ; Leone S; Yates JR; Moore KJ; Fisher EA; Garabedian MJ
    J Biol Chem; 2016 May; 291(21):11172-84. PubMed ID: 27026705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
    Li X; Yeh V; Molteni V
    Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice.
    Hoekstra M; de Jong LM; van der Geest R; de Leeuw LR; Krisnamurthi R; Geerling JJ; Van Eck M
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
    Griffett K; Hayes M; Bedia-Diaz G; Appourchaux K; Sanders R; Boeckman MP; Koelblen T; Zhang J; Schulman IG; Elgendy B; Burris TP
    ACS Chem Biol; 2022 May; 17(5):1143-1154. PubMed ID: 35417135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
    Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
    ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages.
    Vinod M; Chennamsetty I; Colin S; Belloy L; De Paoli F; Schaider H; Graier WF; Frank S; Kratky D; Staels B; Chinetti-Gbaguidi G; Kostner GM
    Biochim Biophys Acta; 2014 Jun; 1841(6):827-35. PubMed ID: 24603323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
    Fessler MB
    Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.
    Peng D; Hiipakka RA; Xie JT; Dai Q; Kokontis JM; Reardon CA; Getz GS; Liao S
    Br J Pharmacol; 2011 Apr; 162(8):1792-804. PubMed ID: 21232031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.